Both in Biotechnology
Taysha Gene Therapies vs Replimune Group
Over the past year TSHA returned −12.9% and REPL returned +70.1%; their daily moves had a correlation of 0.22.
TSHA −12.9% REPL +70.1%Growth of $1, one year, split-adjusted
| Metric | TSHA | REPL |
|---|---|---|
| Price | $4.25 | $15.87 |
| Market cap | $1.38B | $1.50B |
| Today | 0.00% | +21.61% |
| 1 month | −14.8% | +22.1% |
| 6 months | −32.2% | +566.8% |
| Year to date | −22.7% | +63.3% |
| 1 year | −12.9% | — |
| Revenue growth (YoY) | −100.0% | — |
| Gross margin | — | — |
| Net margin | — | — |
| P/E (TTM) | — | — |
| Price / sales | 252.5× | — |
| Net cash | $406.1M | $86.6M |
| Dividend yield | — | — |
| Volatility (60d) | 59.1% | 78.6% |
| Short % of float | 17.6% | 29.6% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).